Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions comprising a combination of an Anti-pd-1 antibody and another antibody

a technology of anti-pd-1 antibody and antibody, which is applied in the field of compositions containing a combination of anti-pd-1 antibody and another antibody, can solve the problems of multiple intravenous injections at different times, and the difficulty of single formulation identification

Inactive Publication Date: 2016-10-20
BRISTOL MYERS SQUIBB CO
View PDF0 Cites 48 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to a pharmaceutical composition comprising a combination of two antibodies or antigen-binding fragments thereof, wherein the ratio of the first antibody to the second antibody is about 50:1 to about 1:50. The first antibody can be an anti-PD-1 antibody or an anti-PD-L1 antibody, and the second antibody can be an anti-CTLA-4 antibody, an anti-LAG3 antibody, or an anti-CD137 antibody. The composition can be used for the treatment of cancer, particularly melanoma, lung cancer, and bladder cancer. The technical effect of the invention is to provide a more effective treatment for cancer by combining two antibodies that target different immune checkpoints.

Problems solved by technology

Nonetheless, administering two antibodies can be burdensome due to different dosing and dosing interval between two antibodies, thereby causing multiple intravenous injections at different time points.
Therefore, while a single formulation containing two antibodies would improve convenience, the unique nature of each antibody makes such a single formulation difficult to identify.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising a combination of an Anti-pd-1 antibody and another antibody
  • Compositions comprising a combination of an Anti-pd-1 antibody and another antibody
  • Compositions comprising a combination of an Anti-pd-1 antibody and another antibody

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0203]A feasibility study was performed to evaluate the stability of ipilimumab and nivolumab in a single fixed dose ratio combination (FDRC) formulation created by mixing the individual formulations of ipilimumab and nivolumab (FIG. 1) to a final ratio of ipilimumab to nivolumab of 1:1.

[0204]Ipilimumab (BMS-734016) DP contains 5 mg / mL ipilimumab in 20 mM Tris-HCl, 100 mM NaCl, 1.0% (w / v) Mannitol, 100 μM pentetic acid (DTPA), and 0.01% polysorbate 80 (PS80), at pH 7.0, and it is available as 40 mL in a 50 mL bottle and 10 ml in a 10 ml vial (FIG. 1). Nivolumab (BMS-936558) DP contains 10 mg / mL nivolumab in 20 mM citrate buffer (sodium citrate dihydrate), 50 mM NaCl, 3.0% (w / v) Mannitol, 20 μM DTPA, and 0.02% PS80, at pH 6.0, and it is available as 10 mL in a 10 ml vial (FIG. 1).

[0205]To achieve a 1:1 ratio of ipilimumab to nivolumab, 80 mL of ipilimumab DP (2 bottles) was mixed with 40 mL of nivolumab DP (4 vials), yielding a combined product having 3.3 mg / mL ipilimumab and 3.3 mg / ...

example 2

[0213]A feasibility study was performed to evaluate the stability of an ipilimumab / nivolumab FDRC created by mixing the individual formulations of ipilimumab and nivolumab to final ratios of 3:1, 1:1, and 1:3 (Table 3). The FDRC formulations were generated by mixing the ipilimumab DS at 5 mg / mL and nivolumab DS at 20 mg / mL to achieve 3:1, 1:1, and 1:3 protein ratios (Table 3). Each combined solution was further mixed with a stir bar at room temperature for 30 min, transferred to vials, and stored for stability over time. The vials were stored at 5° C., 25° C., and 40° C. for up to 12 months.

TABLE 3EC FDRC (3:1; 1:1; 1:3)—Combinations of Formulations of Ipilimumab DP andNivolumab DPFinal Conc'n in Vial:(mg / mL)MannitolNaClDTPAPS 80PrototypeRatioIpiNivopH% w / vmMμM% w / vEC: pH 6.63:14.621.546.61.1596.1593.850.012EC: pH 6.01:32.868.576.01.8678.5765.710.023EC: pH 6.21:14.004.006.21.6783.3373.330.013Prototype EC: pH 6.6, having a 3:1 ratio of ipilimumab to nivolumab, contained 4.62 mg / mL ip...

example 3

[0219]A design of experiments (DoE) study was performed to identify new candidate ipilimumab / nivolumab formulations. Prototype ipilimumab / nivolumab FDRC (3:1) formulations were made in selected histidine or citrate formulations, as shown in Table 4. All DoE FDRC prototypes were prepared to a final concentration of ipilimumab / nivolumab of 10 mg / mL at a ratio of 3:1 (Table 4). FDRC prototype “Combo 4” contained 20 mM citrate, 50 mM NaCl, 50 μM DTPA, 6% w / v sucrose, and 0.05% w / v PS80, at a theoretical pH of 6. FDRC prototype “Combo 5” contained 20 mM histidine, 50 mM NaCl, 50 μM DTPA, 6% w / v sucrose, and 0.05% w / v PS80, at a theoretical pH of 6.0. FDRC prototype “Combo 6” contained 20 mM histidine, 50 mM NaCl, 50 μM DTPA, 6% w / v sucrose, and 0.05% w / v PS80, at a theoretical pH of 7. FDRC prototype “Combo New” contained 20 mM histidine, 50 μM DTPA, 8.5% w / v sucrose, and 0.05% w / v PS80, at a theoretical pH of 6. FDRC prototype “Combo 8,” which was similar to the current nivolumab DP for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to View More

Abstract

This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application claims benefit to U.S. Provisional Application No. 62 / 303,855, filed Mar. 4, 2016; 62 / 269,000, filed Dec. 17, 2015; 62 / 265,268, filed Dec. 9, 2015; and 62 / 149,325, filed Apr. 17, 2015, which are incorporated herein by reference in their entireties.REFERENCE TO A SEQUENCE LISTING SUBMITTED ELECTRONICALLY VIA EFS-WEB[0002]The content of the electronically submitted sequence listing (Name: 3338_0260004_SL.txt; Size: 16,819 bytes; and Date of Creation: Apr. 15, 2016) is herein incorporated by reference in its entirety.[0003]Throughout this application, various publications are referenced in parentheses by author name and date, or by patent number or patent Publication number. The disclosures of these publications are hereby incorporated in their entireties by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C07K16/30
CPCC07K16/2803C07K2317/94C07K16/2878C07K16/28C07K16/30C07K16/3015C07K16/3023C07K16/303C07K16/3038C07K16/3046C07K16/3053C07K16/3069C07K2317/76C07K2317/21C07K16/2818A61K39/39591A61K47/02A61K47/12A61K47/18A61K47/183A61K47/26A61P35/00A61P35/02A61K2039/507A61K9/0019A61P1/04A61P1/18A61P11/00A61P13/00A61P13/08A61P13/10A61P13/12A61P15/00A61P17/00A61P19/00A61P25/00A61P27/02A61P31/00A61P5/00A61K2039/545
Inventor SADINENI, VIKRAMQUAN, YONGKASERER, WALLACE
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com